Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Nov;62(11):1734-6.
doi: 10.1001/archneur.62.11.1734.

Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia

Enzo Emanuele  1 , Angela D'Angelo, Carmine Tomaino, Giuliano Binetti, Roberta Ghidoni, Pierluigi Politi, Livia Bernardi, Raffaele Maletta, Amalia C Bruni, Diego Geroldi
Affiliations
Comparative Study

Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia

Enzo Emanuele et al. Arch Neurol. 2005 Nov.

Abstract

Background: The receptor for advanced glycation end products (RAGE) is a cell surface receptor that has been implicated in vascular disease and neurodegeneration. Low levels of its secreted isoform, soluble RAGE (sRAGE), have been regarded as a putative risk factor for atherosclerosis. In addition, administration of sRAGE has been shown to reduce development of cerebral beta-amyloidosis in an Alzheimer disease mouse model.

Objective: To investigate the role of sRAGE as a biological marker for Alzheimer disease and vascular dementia.

Design: Cross-sectional study of 152 patients with a clinical diagnosis of Alzheimer disease, 91 with vascular dementia and 161 control subjects.

Main outcome measure: Plasma levels of sRAGE.

Results: Levels of sRAGE were significantly reduced in the plasma of patients with Alzheimer disease compared with that for those with either vascular dementia (P<.05) or with controls (P<.001).

Conclusions: Patients with Alzheimer disease have reduced levels of sRAGE in plasma compared with patients with vascular dementia and controls. The striking reduction of circulating sRAGE in Alzheimer disease further supports a role for the RAGE axis in this clinical entity and requires further investigation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

Substances